ClinicalTrials.gg
RecruitingNCT07938164ACUTE-GOUpdated Nov 16, 2026

ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute Gouty Arthritis Flares

A Phase 4 interventional study of Purified Cortophin Gel, 40 U and Purified Cortophin Gel 80 U in Acute Gouty Arthritis, sponsored by ANI Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by ANI Pharmaceuticals · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Planned enrollment
52nd of 149
160 · median 74
Started
2026
with 5 others
Phase 4
22 of 164
4 open now
Primary completion
2027-11
later than 8 of 15 live
Registered
163rd of 164
by date

Among the 164 studies in Gout with a site in United States, this one is the 52nd largest by planned enrollment of the 149 interventional ones that give a count, is one of 6 that started in 2026, is one of 22 in phase 4, reaches primary completion later than 8 of the 15 other live ones, and was the 163rd registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Purified Cortrophin Gel can help people with acute gouty arthritis when they are having a sudden flare-up. It will also monitor participants for any potential side effects while on this therapy. The main question it aims to answer is: is there a change in gout pain intensity after receiving Purified Cortrophin Gel.

Researchers will compare two different doses of Purified Cortrophin Gel.

Participants will:

  • Receive one injection of Purified Cortrophin Gel
  • Have 2 in-person visits to the site and 3 virtual/telephone visits
  • Complete daily surveys about their gout flare
03

Conditions studied

  • Acute Gouty Arthritis

Browse trials for

Keywords

  • gout
  • gout flare
  • pcg
  • purified cortrophin gel
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  1. Signed to participate in this study.
  2. Male and female patients, aged 18-90 years.
  3. Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative.
  4. Onset of current acute gout flare within 5 days prior to study entry
  5. Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS).
  6. History of ≥ 1 gout flares within the 12 months prior to study entry
  7. The patient meets at least one of the following criteria for NSAIDs or colchicine treatment options:

    1. Minimum of one episode of inadequate response to treatment.
    2. The investigator deems that the patient is either or inappropriate for treatment with NSAIDs or colchicine. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication).
  8. Patients must be willing and capable of using, and have access to, an electronic device (e.g., cellphone or internet connected computer/tablet) to be able to complete surveys.

Main exclusion criteria:

  1. Patients with active or known history of scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, or ocular herpes simplex.
  2. Recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)).
  3. Patients with active or known history of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, or uncontrolled diabetes type 1 or 2, as deemed by investigator.
  4. Patients with sensitivity to proteins derived from porcine sources.
  5. Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.
  6. Active flare of rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at baseline.
  7. Polyarticular gouty arthritis flare currently active in more than 4 joints.
  8. Patients who have taken an drug within five times the half-life of that investigational drug has passed or within 30 days of randomization.
  9. Previous inclusion in this study.
  10. Patients currently receiving dialysis.
  11. Uncontrolled hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.
  12. Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.
  13. Prior or current treatment with any ACTH product.
  14. Pregnant or nursing (lactating) women. Women of are required to be using an acceptable method of .

    1. Contraception must be used for the entire study and for at least 30 days after the last dose of study drug.
    2. Acceptable methods of contraception are:

    i. hormonal methods, such as birth control pills, patches, injections, vaginal rings, or implants ii. barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) iii. intrauterine device (IUD) iv. abstinence (no sex)

  15. Patients taking urate-lowering therapy have to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.
  16. Use of specified pain relief medications or biologics (including , narcotics, paracetamol/acetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor [TNF] inhibitors) within specified periods prior to randomization.
  17. Vaccination within 30 days prior to study enrollment and during the study period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    40 U Purified Cortrophin Gel

    Drug: Purified Cortophin Gel, 40 U

  • Active comparator
    80 U Purified Cortrophin Gel

    Drug: Purified Cortophin Gel 80 U

Interventions

  • DrugPurified Cortophin Gel, 40 U

    One injection of Purified Cortrophin Gel, 40 U

  • DrugPurified Cortophin Gel 80 U

    One injection of Purified Cortrophin Gel, 80 U

06

What researchers measure

Primary outcomes

  1. Change in gout pain intensity from baseline in the target joint following PCG administration.

    Change in gout pain intensity from baseline in the target joint following PCG administration measured by Visual Analog Scale (VAS) at 72 hours post-injection (Day 3) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain.

    Time frame: From baseline to Day 3

Secondary outcomes

  1. Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured by Visual Analog Scale (VAS) at Day 1 (24 hours post-injection)

    Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured at Day 1 (24 hours post-injection) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100

    Time frame: Baseline to Day 1

  2. Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured by Visual Analog Scale (VAS) at Day 2 (48 hours post-injection)

    Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain.

    Time frame: Baseline to Day 2

  3. Change in pain intensity timeline at baseline, 24 hours, 48 hours, 72 hours, and Day 7 post-injection

    Time frame: Baseline to Day 7

  4. Time to onset of effect (≥20% change from baseline pain intensity on VAS)

    Time frame: Baseline to Day 7

  5. Time to response (≥50% change from baseline pain intensity on VAS)

    Time frame: Baseline to Day 7

  6. Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale)

    Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale) 24 hours, 48 hours, 72 hours, and Day 7 post-injection scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response.

    Time frame: Baseline to Day 7

  7. Physician-Assessed Inflammatory Signs of the Index Joint (Joint Tenderness, Swelling, Range of Motion, and Erythema)

    Investigator-assessed composite of inflammatory signs in the index (most affected) joint, evaluated at baseline (Day 0) and 72 hours post-injection (Day 3): Joint tenderness - assessed via palpation/passive motion on a 4-point Likert scale: 0 (no pain) to 3 (severe/patient winces and withdraws); lower scores indicate better outcome. Joint swelling - 4-point Likert scale: 0 (no swelling) to 3 (severe swelling/bulging beyond joint margins); lower scores indicate better outcome. Target joint range of motion - 5-point Likert scale: 0 (normal) to 4 (immobilized); lower scores indicate better outcome. Erythema - categorical assessment: present, absent, or not assessable.

    Time frame: Baseline to Day 3

  8. Physician assessment of local tolerability at injection site (at 72 hours post-injection) - Number of Participants with Injection Site Reactions (Adverse Events)

    Local tolerability at the injection site will be assessed via investigator-reported adverse events. Injection site reactions occurring after study drug administration will be captured. The AE will be graded based on severity: MILD/MODERATE/SEVERE and causality: related/not related to study drug.

    Time frame: Baseline to Day 3

  9. Physician's Global Assessment of Response to Treatment (5-Point Likert Scale)

    Physician's Global Assessment of Response to Treatment (5-Point Likert Scale) scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response.

    Time frame: Baseline to Day 3

  10. Use of rescue medication (up to 72-hours post-injection)

    Time frame: Baseline to Day 3

  11. Safety and Tolerability Assessments (Adverse Events, Serious Adverse Events, Clinical Laboratory Parameters, and Vital Signs)

    Safety will be assessed as follows: Adverse Events (AEs) and Serious Adverse Events (SAEs) - collected from study drug administration through Day 7, graded by the investigator as MILD, MODERATE, or SEVERE, and assessed for causality (related/not related to study drug). Clinical laboratory safety parameters - collected at baseline (Day 0) and Day 3, including biochemistry (AST, ALT, total bilirubin, ALP, PT/INR, albumin, total/LDL/HDL cholesterol, triglycerides, creatinine, sodium, potassium, ferritin, uric acid, glucose, HbA1c, troponin T, CRP, calcium, magnesium), hematology (hemoglobin, hematocrit, WBC with differential, platelets, ESR), and urinalysis (albumin, erythrocytes, hCG where applicable). Vital signs - systolic and diastolic blood pressure (mmHg), heart rate (bpm), and body temperature (°F), collected at baseline (Day 0) and Day 3, following a 5-minute rest period.

    Time frame: Baseline to Day 7

Other outcomes

  1. Change from Baseline in Serum C-Reactive Protein (CRP) Level

    Levels of C-reactive protein inflammatory markers (baseline \[Day 0\], 72 hours \[Day 3\]) continuous biomarker in mg/L (confirm units with your lab). Increasing CRP reflects worsening inflammation

    Time frame: Baseline to Day 3

  2. Change from Baseline in Gout Attack Intensity Score (GAIS)

    Change from baseline in health-related quality-of-life Gout Attack Intensity Score (GAIS) at Day 0 and at Day 3 (72-hours post-injection). GAIS is the mean of 3 patient-reported items (pain, tenderness, swelling), each scored 1-5; range 1-5, with higher scores indicating worse (more severe) gout attack intensity.

    Time frame: Baseline to Day 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2027, 22 months after the start.

Of 18 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Nov 16, 2026
StartActual
Jan 28, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938164
Lead sponsor
ANI Pharmaceuticals
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 28, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Ashley Gantt
Contact
ashley.gantt@anipharmaceuticals.com
678-527-1332

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion